Integra LifeSciences Holdings (IART) Reports In-Line Q3 EPS; Cuts FY11 EPS Outlook
Integra LifeSciences Holdings (NASDAQ: IART) reported Q3 EPS of $0.77, in-line with the analyst estimate of $0.77. Revenue for the quarter came in at $202.2 million versus the consensus estimate of $204.15 million.
Integra sees FY2011 EPS of $2.88-$2.96, versus prior guidance of $2.92-$3.02 and the consensus of $2.93.
Integra sees FY2011 EPS of $2.88-$2.96, versus prior guidance of $2.92-$3.02 and the consensus of $2.93.